Christine CHEVREAU
Institut Universitaire du Cancer Toulouse Oncopole · IUCT-O · Institut Claudius Regaud
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christine CHEVREAU as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:02 UTC. Open this list on ClinicalTrials.gov
- N/ANCT03263416 · Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a Dedicated and Coordinated Follow-up Compared to Standard Follow-up.Institut Claudius Regaud · completed · Metastatic Solid Tumor · principal investigator
- Ph4NCT02555748 · Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaInstitut Claudius Regaud · completed · Metastatic Renal Cell Cancer · principal investigator
- Ph2NCT00864318 · Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad PrognosisInstitut Claudius Regaud · completed · Germ Cell Tumors · principal investigator
- Ph2NCT00814021 · Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the BrainInstitut Claudius Regaud · completed · Kidney Cancer, Metastatic Cancer · study chair
- N/ANCT00695032 · Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid TumorsInstitut Claudius Regaud · suspended · Chemotherapeutic Agent Toxicity, Renal Toxicity, Unspecified Adult Solid Tumor, Protocol Specific · study chair
- Ph2NCT00210041 · Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid CarcinomaInstitut Claudius Regaud · completed · Genital Neoplasms, Male · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:02 UTC. The ranking covers the 200 most relevant of 116 PubMed records, and a shared surname and initials can bring in a namesake. All 116 on PubMed
- Sorafenib in advanced clear-cell renal-cell carcinoma.N Engl J Med · 20074,005 citationsRCR 91.1
- 1,791 citationsRCR 39.3
- Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.J Clin Oncol · 2009888 citationsRCR 20.6
- Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.N Engl J Med · 1998799 citationsRCR 16.7
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.N Engl J Med · 2018746 citationsRCR 28.0
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.N Engl J Med · 2021663 citationsRCR 34.9
- Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.J Clin Oncol · 2008504 citationsRCR 12.9
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.JAMA Oncol · 2018365 citationsRCR 12.0
- 361 citationsRCR 9.3
- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.Lancet Oncol · 2020276 citationsRCR 13.1